Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy

Radiotherapy and Oncology

Volumn 71, Issue 2, 2004, Pages 163-166

  Thirion, Pierre ^a   Holmberg, Ola ^a,b   Collins, Conor D ^a   O'Shea, Carmel ^a   Moriarty, Michael ^a   Pomeroy, Maeve ^a   O'Sullivan, Catriona ^a   Buckney, Steve ^a   Armstrong, John ^a  

^a ST LUKE S HOSPITAL   (Ireland)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acceleration; Dose escalation; Hypofractionation; Non small cell lung cancer; Three dimensional conformal radiation therapy

Indexed keywords

CARBOPLATIN; PACLITAXEL; STEROID;

ACUTE TOXICITY; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHEMOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; CYTOLOGY; DOSE RESPONSE; ESOPHAGITIS; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; PLEURA EFFUSION; PRIORITY JOURNAL; RADIATION DOSE; RADIATION HAZARD; RADIATION INJURY; RADIATION PNEUMONIA; SPINAL CORD; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIATION INJURIES; RADIATION TOLERANCE; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RISK ASSESSMENT; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 1942542250     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2003.09.006     Document Type: Article

References (20)

1. Ang K.K., Thames H.D., Peters L.J. Altered frationation schedules. Perez C.A., Brady L.W. Principles and practice of radiation oncology. 3rd ed. 1998;119-142 Lippincott-Raven, Philadelphia, PA.
2. Armstrong J., Burman C., Leibel S.A., et al. Conformal three dimensional treatment planning may improve the therapeutic ratio of high dose radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys. 26:1993;685-689.
3. Armstrong J., Zelefsky M.J., Leibel S.A., et al. Strategy for dose escalation using 3-dimensional conformal radiation therapy for lung cancer. Ann Oncol. 6:1995;693-697.
4. Arriagada R., Le Chevalier T., Quoix E., et al. ASTRO plenary: effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. Int J Radiat Oncol Biol Phys. 20:1991;1183-1189.
5. Cox J.D., Pajak T.F., Asbell S., et al. Interruption of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 radiation therapy oncology group (RTOG) trials. Int J Radiat Oncol Biol Phys. 27:1993;493-498.
6. Cox J.D., Stetz J., Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 31:1995;1341-1346.
7. Fowler J.F., Chappell R. Non-small cell lung tumors repopulate rapidly during radiation therapy. Int J Radiat Oncol Biol Phys. 46:2000;516-517.
8. Green S., Weiss G.R. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Investig New Drugs. 10:1992;239-253.
9. Hayman J.A., Martel M.K., Haken T., et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol. 19:2001;127-136.
10. International Union Against Cancer (UICC): Lung (IDC-O C-34). Sobin L.H., Wittekind C.H. TNM classification of malignant tumors. 5th ed. 1997;93-97 Wiley, New York.
11. Marks L.B., Garst J., Socinski A., et al. The maximally tolerated dose of accelerated hyperfractionated conformal radiation therapy (RT) following carboplatin/taxol (CT) or carboplatin/navelbine (CN) for unresectable non small cell cancer: a phase I dose escalation study from the Carolina Conformal Therapy Consortium (Abstr.). Proc Am Soc Clin Oncol (ASCO). 20:2001;330a.
12. Martel M.K., Ten Haken R.K., Hazuka M.B., et al. Estimation of tumor control probability model parameters from 3-D dose distribution of non-small cell lung cancer patients. Lung Cancer. 24:1999;31-37.
13. Mehta M., Scrimger R., Mackie R., Paliwal B., Chappell R., Fowler J. A new approach to dose escalation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 49:2001;23-33.
14. Perez C.A., Pajak T.F., Rubin P., et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer. 59:1987;1874-1881.
15. Rozenzweig K.E., Sim S.E., Mychalczaczak B., Braban L.E., Schindelheim R., Leibell S.A. Elective nodal irradiation in the treatment of non-small-cell cancer with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 50:2001;681-685.
16. Saunders M., Dische S., Barrett A., Harvey A., Gibson D., Parmar M. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy non-small-cell lung cancer: a randomised multicentre trial. Lancet. 350:1997;161-165.
17. Schaake-Koning C., Van den Bogaert W., Dalesio O., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung carcinoma. N Engl J Med. 326:1992;523-530.
18. Simpson J.R., Bauer M., Wasserman T.H., et al. Large fraction irradiation with or without misonidazol in advanced non-oat cell carcinoma of the lung: a phase III randomised trial of the RTOG. Int J Radiat Oncol Biol Phys. 13:1987;861-867.
19. Thirion P., Collins C.D., Holmberg O., et al. Phase I/II trial of hypofractionated high-dose radiation scheme using 3-dimensional conformal radiotherapy in patients with non-resectable non-small-cell lung carcinoma. Radiology. 173:(Suppl. 1):2003;173. (Abstr. 268RO).
20. WHO Handbook for Reporting Response. Geneva: WHO; 1979.